Home Gastrointestinal Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Per

Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Per


Jon Arne Søreide1,2

1Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway; 2Department of Clinical Medicine, University of Bergen, Bergen, Norway

Correspondence: Jon Arne Søreide
Department of Gastrointestinal Surgery, Stavanger University Hospital, POB 8100, Stavanger N-4022, Norway
Tel +47 905 31770
Fax +47 51519919
Email [email protected]

Abstract: Hepatoid adenocarcinoma of the stomach (HAS) is a rare subgroup of gastric cancer (GC). Morphologically, this tumor exhibits both adenocarcinomatous and hepatocellular differentiation, and most tumors show immunohistochemical staining for alpha-fetoprotein (AFP) or elevated AFP serum levels. The diagnosis of HAS is frequently delayed, and at least half of patients have advanced disease at the time of diagnosis. Despite a lack of evidence, treatment approaches have mostly followed principles for the treatment of common gastric cancer (CGC), including radical surgery in eligible patients with curative intent. The indications for and the type of adjuvant systemic treatments remain unclear. Additionally, there is a lack of evidence allowing any firm conclusions to be drawn regarding the best treatment for patients with metastatic HAS (mHAS). Chemotherapy regimens, including cisplatin-based chemotherapy, are considered the most efficient first-line systemic treatment in advanced situations. Their combination with targeted therapy (i.e., trastuzumab) in HER2-positive tumors seems promising. The rarity of these patients and the scarce and heterogeneous literature on this particular subgroup of GC make it difficult to provide any robust evidence for the clinical management of patients with HAS.

Keywords: hepatoid adenocarcinoma, stomach, gastric, alpha-fetoprotein, therapy, prognosis

Creative Commons License
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.

By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

This site uses Akismet to reduce spam. Learn how your comment data is processed.